Lifeboat Foundation

From insilico meddicine — the beginning of an AI healthcare revolution.

Poly Mamoshina on Machine Learning for small molecule drug discovery and the beginning of an AI healthcare revolution — interviewed at the Undoing Aging conference in Berlin 2019!

Continue reading “Polina Mamoshina — The Beginning of an AI Healthcare Revolution” »

Whenever I see my 10-year-old daughter brimming over with so much energy that she jumps up in the middle of supper to run around the table, I think to myself, “those young mitochondria.” Mitochondria are our cells’ energy dynamos.

The Universe is not what textbook physics tells us except that we perceive it in this way – our instruments and measurement devices are simply extensions of our senses, after all. Reality is not what it seems. Deep down it’s pure information – waves of potentiality – and consciousness creating it all. https://www.ecstadelic.net/top-stories/the-alpha-point-vs-th…sciousness #AlphaPoint vs. #OmegaPoint

“Each of us appears in the divine play in a dual role of creator and actor. A full and realistic enactment of our role in the cosmic drama requires the suspension of our true identity. We have to forget our authorship and follow the script.”

-Stanislav Grof

Continue reading “The Alpha Point vs. the Omega Point: Ours is one of the possible worlds simulated in absolute consciousness” »

Read more

A new study shows that short-term treatment with the common organ rejection drug rapamycin reverses periodontal bone loss, attenuates inflammation, and makes the oral microbiome revert to a more youthful state in old mice.

What is rapamycin?

Rapamycin (also known as sirolimus) is a macrolide, a class of antibiotics that includes Biaxin (Clarithromycin), Zithromax (Azithromycin), Dificid (Fidoximycin), and Erythromycin. Macrolides inhibit the growth of bacteria and are often used in the treatment of common bacterial infections.

Nearly one in six deaths from prostate cancer could be prevented if targeted screening was introduced for men at a higher genetic risk of the disease, according to a new UCL-led computer modelling study.

Prostate cancer is the most common form of cancer in men with around 130 new cases diagnosed in the UK every day and more than 10,000 men a year dying as a result of the disease. However, unlike breast and cervical cancer there is currently no national screening programme for this disease in the UK.

A blood test that detects raised levels of the prostate-specific antigen (PSA) can be used to screen for prostate cancer. However, this test is not a reliable indicator as it does not accurately distinguish between dangerous cancers from harmless ones—leading to both unnecessary operations and missed cancers that are harmful.

Every year, we’re reminded to return to the pharmacy for a flu shot. Why can’t we have a flu vaccine that offers long-term protection, like those for measles or polio? That’s because the influenza virus continuously evolves, so the immune response we build up one year might not work the next year—or even on the version of the flu you catch the same year. As a result, the virus remains dangerous: last year, it caused more than 60,000 deaths in the United States alone.

New findings, published in Cell, reveal why making a general-purpose vaccine that guards against all versions of the flu is so hard: Instead of improving its memory of the previous version of virus, the immune system develops its response to the new virus variant from scratch, mostly using immune cells that have no memory of the virus.

“If we can figure out how to help the immune system to keep building on what it has already learned, we could develop better vaccines for highly evolving viruses like the flu, or HIV, or Hepatitis C,” says Gabriel D. Victora, assistant professor at Rockefeller.

P53 is the most famous cancer gene, not least because it’s involved in causing over 50% of all cancers. When a cell loses its p53 gene—when the gene becomes mutated—it unleashes many processes that lead to the uncontrolled cell growth and refusal to die, which are hallmarks of cancer growth. But there are some cancers, like kidney cancer, that that had few p53 mutations. In order to understand whether the inactivation of the p53 pathway might contribute to kidney cancer development, Haifang Yang, Ph.D., a researcher with the Sidney Kimmel Cancer Center—Jefferson Health probed kidney cancer’s genes for interactions with p53.

Earlier work found that PBRM1—the second most mutated gene in kidney cancer—could interact with p53. However, other researchers were unable to definitively show that it was truly an important mechanism in kidney cancer.

Rather than looking at the p53 protein itself, first author Weijia Cai a postdoc in Dr. Yang’s lab and other collaborators looked at an activated version of p53, one that is studded with an additional chemical marker—an acetyl group—at many specific spots.

Marcos López de Prado has been at the forefront of machine learning innovation in finance. The New-York based Spaniard was the first-ever head of machine learning at AQR, one of the world’s largest investment management firms, before he left earlier this year to start his own firm, which sells machine learning expertise and algorithms to Wall Street.

Science, not speculation, is the right way to invest, a top expert tells TIME.